Comparison of the cardiovascular presentations, complications and outcomes following different coronaviruses’ infection: A systematic review

Mohammad Mostafa Ansari Ramandi1,4, Hossein Yarmohammadi2, Somayeh Beikmohammadi1, Behzad Hassan Hosseiny Fahimi1, Farbod Hatami1, Hossein Beydokhti3, Hooman Bakhshandeh5, Nasim Naderi2*

Introduction
The novel coronavirus disease 2019 (COVID-19) pandemic has rapidly spread in many countries around the world. As of June 18, 2020, more than 8 million people have been infected, with near to 440,000 deaths. COVID-19 is affecting adults more than children specially those younger than 15 years of age. The three main symptoms of the infection are cough, shortness of breath and fever. Some other symptoms include headache, malaise and sore throat which are less common. Most of these symptoms are presentations of respiratory tract infection. However, there have been reports about symptoms which overlap with cardiovascular symptoms. Some of these patients have underlying cardiovascular diseases, which affects their disease progression and outcome, but others might also present with cardiovascular manifestations. They might either present with cardiovascular findings or develop cardiovascular complications. But this is not the first time for cardiovascular presentations of coronavirus. There have been some studies reporting these presentations by previously known strains of the coronavirus family. Severe acute respiratory syndrome (SARS) caused by SARS-associated coronavirus has presented itself in many ways during the previous years. Studying the previous presentations of coronavirus family and the recent cardiovascular manifestations of COVID-19 can help in predicting possible future challenges and taking measures to tackle these issues. The aim of this systematic review was to gather cardiovascular manifestations caused by coronavirus family have presented it in many ways during the previous years. The aim of this systematic review was to gather all possible cardiovascular manifestations of the coronavirus family in the literature. Adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched PubMed, Scopus, Web of Science, Cochrane and ProQuest which were updated on May 1, 2020 for the last time. Regarding to the novelty and speed of publications on COVID-19, we searched Google Scholar and also references of included studies and review articles in the systematic search results were searched manually. The searched keywords were the combination of the following MeSH terms: “COVID-19”, “SARS”, “MERS” and “cardiovascular presentation”. The systematic review was registered with ID CRD42020180736 in International Prospective Register of Systematic Reviews (PROSPERO). After screening, 28 original articles and ten case studies (five case reports and five case series) were included. Most of the studies were focused on COVID-19 (20 original articles and five case studies) while the only studies about Middle East Respiratory Syndrome (MERS) was a case report. Almost all the cardiovascular presentations and complications including acute cardiac injury, arrhythmias and the thrombotic complications were more prevalent in COVID-19 than severe acute respiratory syndrome (SARS) and MERS. The cardiac injury was the most common cardiovascular presentation and complication in COVID-19 whereas thrombotic complications were commonly reported in SARS. The cardiac injury was the predictor of disease severity and mortality in both COVID-19 and SARS. Coronavirus 2019 may present with cardiovascular manifestations and complications in signs and symptoms, laboratory data and other paraclinical findings. Also, cardiovascular complications in the course of COVID-19 may result in worse outcomes.

*Corresponding Author: Nasim Naderi, Email: naderi.nasim@gmail.com

© 2021 The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Coronaviruses and the cardiovascular system

Material and Methods

Search strategy
PubMed, Scopus, Web of Science, Cochrane and ProQuest were searched systematically based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline and updated on May 1, 2020 for the last time. Regarding to the novelty and speed of publications on COVID-19, we searched Google Scholar and also references of included studies and review articles in the systematic search results were searched manually. The searched keywords were the combination of the following MeSH terms: “COVID-19”, “SARS”, “MERS” and “cardiovascular presentation”. The systematic review was registered with ID CRD42020180736 in PROSPERO International prospective register of systematic reviews and the complete search strategy is available online. On May 6, 2020, we added another researcher who helped in carrying on the systematic review to the PROSPERO. We also added the search strategy for all databases that were used. There were no changes in the protocol during the review.

Study selection
Interventional or descriptive studies on cardiovascular manifestations or complications of confirmed cases of three Coronaviruses including COVID-19, MERS and SARS were included in the study. There was no limitation on the year of publication or age of the study population. However, only articles in English Language were included. Case reports and letters were not excluded. Animal studies, reviews and guidelines were considered as exclusion criteria. Title, abstract and full text of search results were screened by two investigators independently and in any case of disagreement, the third senior investigator was asked to make the decision after discussion about the issue.

Our outcomes of interest were the various cardiovascular specific presentations, the cardiovascular related laboratory and imaging findings, complications and outcomes in SARS, MERS and COVID-19.

Data extraction
For each included study, the type of Coronavirus infection, year and country of publication, and the name of the first author were summarized into a table. Reported cardiovascular presentations and complications with their prevalence in the study population if available, were gathered and their impact on outcomes of the disease were added to the table. The data extraction was performed by two investigators independently and the third investigator was asked to participate in the case of disagreement.

Quality assessment
For quality assessment, the Quality Assessment Tool for Studies with Diverse Designs (QATSDD) was used. Two investigators assessed each study independently and the third investigator was asked to make the decision in the case of disagreement. The quality assessment was only done for original articles and case studies were not assessed. Also, quality assessment was not done for excluded articles. The QATSDD consists of 16 questions that 2 of them are for qualitative studies only. For each question there is a possible score 0 to 3 that makes the highest possible score to be 42. After scoring each question, the overall score for each article was calculated and then the percentage of the 42 was determined.

Results
After screening, 28 original articles and 10 case studies (5 case reports and 5 case series) were included. Most of the studies were focused on COVID-19 (20 original articles and four case studies), and 12 articles (eight original and four case studies) were focused on SARS. While there were only two studies about MERS. The PRISMA flow diagram is shown in Figure 1. Quality of most 20 studies was more than 70%. The range of the percent of quality was 40% to 88%. Original studies were retrospective in 22 articles and China was the origin of most of the articles. The original articles and case reports are summarized in Table 1 and Table 2 respectively.

Original studies

Cardiovascular presentation
Ten COVID-19 manuscripts reported cardiac injury as the cardiovascular presentation of patients. However, only three manuscripts reported elevated creatine kinase levels in SARS patients without a significant increase in the MB isoform. Seven (one original study and six case studies) manuscripts reported electrocardiography changes and arrhythmias such as ventricular fibrillation and tachycardia as the presentation of patients infected with coronaviruses.

Cardiovascular complication
From the COVID-19 manuscripts, eight studies reported cardiac injury as a complication of the infection with incidence of 7.4%-77% according to the included patients’ disease severity. Heart failure was reported as the complication in four manuscripts with an incidence of 1%-49%. Regarding arrhythmias, only two studies reported them as the complication of COVID-19 infection with an incidence of 10.4%-60%. Studies related to SARS infection reported ischemic strokes, deep vein thrombosis (DVT), pulmonary embolism and cardiomegaly as cardiovascular complications of the infection.

Cardiovascular outcome
Most studies reported cardiac injury as predictors of
disease severity and mortality. Some studies indicated that patients who had cardiac injury needed more intensive care unit hospitalization. Acute myocardial infarction, arrhythmias and heart failure were regarded as the cause of death in some patients.

**Case studies**
Table 2 summarizes the different cases reported with COVID-19, SARS and MERS infection and their cardiovascular presentations, complications or outcomes. Overall, the cases included patients experiencing cardiogenic shock, myocarditis, ischemic stroke, myocardial infarction, DVT and pulmonary embolism.

**Discussion**
As experience with COVID-19 grows, the management of cardiovascular problems has become one of the most important challenges in caring process of these patients. While the world is in the grip of the COVID-19 pandemics, we took a look back at SARS and MERS and tried to show differences and similarities between the three kind of Coronavirus infection in terms of cardiovascular manifestations and outcomes.

A similar pathogenesis has been suggested for three viruses. It has also been shown that the presence of cardiovascular comorbidities is accompanied with more severe illness and mortality in all three cases of Coronavirus infection.\(^1\)\(^4\)\(^3\)\(^4\)\(^5\) However, although the pandemics of COVID-19 has not ended, besides its reproductive number which is significantly higher in COVID-19 than SARS and MERS and their similarities such as more infection in adult and men, it seems that COVID19 compared to the other Coronavirus infections is more possible to manifest with a cardiovascular sign and symptom\(^3\)\(^4\)\(^4\)\(^1\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)\(^1\)\(^4\)\(^3\)\(^4\)...
Table 1. Included original studies in the manuscript

| Coronavirus family | Author       | Place, year | Design (No) | Cardiovascular presentations, No (percentage) | Cardiovascular complications, No (percentage) | Cardiovascular outcome, No (percentage) | Quality (%) |
|-------------------|--------------|-------------|-------------|---------------------------------------------|---------------------------------------------|-----------------------------------------|-------------|
|                   | Guo et al. 1| China, 2020 | Retrospective, single center (187) | Myocardial injury 52 (27.8%) | VT/VF 11 (5.9%) | NA | Patients with myocardial injury had: | More males | 71 |
|                   |             |             |             | NA | NA | NA | Higher age | |
|                   |             |             |             | NA | NA | NA | Shorter duration of symptoms to death or discharge | |
|                   |             |             |             | NA | NA | NA | Higher mortality | |
|                   |             |             |             | NA | NA | NA | More complications | |
| COVID-19           | Yan et al. 10| China, 2020 | Retrospective, single center (135) | NA | Acute cardiac injury 10 (7.4%) | NA | Patients with higher CK MB: | Were more severe case | 76 |
|                   |             |             |             | NA | NA | NA | More need for ICU care | |
|                   | Huang et al. 7| China, 2020 | Prospective, multicenter (41) | NA | Acute cardiac injury 5 (12%) | NA | Patients with acute cardiac injury had: | 83 |
|                   |             |             |             | NA | NA | NA | More need for ICU care | |
|                   | Zhou et al. 22| China, 2020 | Retrospective, multicenter (191) | NA | Acute cardiac injury 33 (17%) | Heart failure, 44 (23%) | Patients with acute cardiac injury or heart failure had: | 78 |
|                   |             |             |             | NA | NA | NA | Higher mortality | |
|                   | Chen et al. 9| China, 2020 | Retrospective, single center (274) | HscTnl > 15.6 pg/mL, 83/203 (41%) | Acute cardiac injury, 72/94 (77%) | Heart failure, 41/183 (46%) | Patients with cardiovascular complications had: | Higher mortality | 78 |
|                   |             |             |             | NA | NA | NA | Cause of death: | |
|                   | Du et al. 21| China, 2020 | Retrospective, multicenter (85) | CK=170 U/L, 31 (36.5%) | Acute cardiac injury, 38 (44.7%) | HscTnl 51 (60%) | Cause of death: | Cardiac arrest, 7/81 (8.64%) | 69 |
|                   |             |             |             | NA | NA | NA | Acute coronary syndrome, 4/81 (4.94%) | |
|                   |             |             |             | NA | NA | NA | Major atrial fibrillation, 2/81 (2.47%) | |
|                   | Chen et al. 15| China, 2020 | Experimental study on human heart tissue, single center (45) | SARS-CoV-2 might attack pericytes, and cause capillary endothelial cell dysfunction | NA | NA | Cause of death: | 42 |
|                   |             |             |             | NA | NA | NA | Cardiovascular injury | |
|                   | Guan et al. 19| China, 2019 | Retrospective, multicenter (1099) | CK > 200 U/L, 90/657 (13.7 %) | NA | NA | Cause of death: | 85 |
|                   |             |             |             | NA | NA | NA | Cardiovascular injury | |
|                   | Zhang et al. 11| China, 2020 | Retrospective, single center (140) | Increased serum CK, 4/80 (6.7%) | NA | NA | Cause of death: | 71 |
|                   |             |             |             | NA | NA | NA | Cardiovascular injury | |
|                   | Wang et al. 16| China, 2020 | Retrospective, single center (339) | 14 abnormal ECGs in cardiac injury patients: myocardial ischemia, T-wave depression and inversion, ST-segment depression, and Q-waves | Acute cardiac injury, 70 (21.0%) | HscTnl, 35 (10.4%) | Cause of death: | 83 |
|                   |             |             |             | NA | NA | NA | Cardiovascular injury | |
|                   |             |             |             | NA | NA | NA | Increased serum hscTnl | |
|                   | Shí et al. 30| China, 2020 | Retrospective observational cohort, single center (416) | One patient developed severe respiratory failure, heart failure, and sepsis: Expired due to sudden cardiac arrest on the 11th day of admission. | NA | NA | Cause of death: | 88 |
|                   |             |             |             | NA | NA | NA | Cardiovascular injury | |
|                   | Chen et al. 20| China, 2020 | Retrospective, single center (99) | Elevated CK, 13 (13%) | NA | NA | Cause of death: | 69 |
|                   |             |             |             | NA | NA | NA | Cardiovascular injury | |
|                   | Yang et al. 21| China, 2020 | Retrospective, single center (52) | Cardiac injury, 12 (23%) | NA | NA | Cause of death: | 54 |
|                   |             |             |             | NA | NA | NA | Cardiovascular injury | |
|                   | Bonetti et al.25| Italy, 2020 | Retrospective, single center (144) | NA | NA | NA | Cause of death: | Non- survivors had higher values of: | 71 |
|                   |             |             |             | NA | NA | NA | CK, HscTnl | |
|                   | Zheng et al. 18| China, 2020 | Retrospective, single center (161) | CK > 190 U/L, 17 (10.6 %) | NA | NA | Cause of death: | 76 |
|                   |             |             |             | NA | NA | NA | Cardiovascular injury | |
|                   | Han et al. 23| China, 2020 | Retrospective, single center (273) | CK-MB > 5 mg/ml, 10 (3.68%) | Ultra-TnI > 0.04 mg/ml, 27 (9.89%) | NT-proBNP > 900 pg/mL, 34 (12.45%) | Cause of death: | 76 |
|                   |             |             |             | NA | NA | NA | Cardiovascular injury | |
|                   | Yang et al. 26| China, 2020 | Retrospective, single center (92) | NA | Cardiac Injury, 31/91 (34.1%) | NA | Cause of death: | 47 |
|                   |             |             |             | NA | NA | NA | Cardiovascular injury | |
|                   | Deng et al. 29| China, 2020 | Retrospective single center (112) | LV/EF <50%, 6 (6.4%) | Possible myocarditis, 14 (12.5%) | ST-segment elevation, 22 (19.6%) | Cause of death: | 78 |
|                   |             |             |             | NA | NA | NA | Cardiovascular injury | |
|                   |             |             |             | NA | NA | NA | Cardiovascular injury | |
|                   | Hong et al. 27| South Korea, 2020 | Retrospective, single center (98) | NA | Acute cardiac injury, 11 (11.2%) | NA | Cause of death: | 69 |
|                   |             |             |             | NA | NA | NA | Cardiovascular injury | |
|                   | Zheng et al. 28| China, 2020 | Retrospective, single center (99) | NA | NA | NA | Cause of death: | 40 |
|                   |             |             |             | NA | NA | NA | Cardiovascular injury | |
### Table 1. Continues

| Coronavirus family | Author | Place, year Design (No) | Cardiovascular presentations, No (percentage) | Cardiovascular complications, No (percentage) | Cardiovascular outcome, No (percentage) | Quality (%) |
|--------------------|--------|------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------|-------------|
| SARS               | Siu-lung li et al. | Hong Kong, 2003 Prospective, single center (46) | • RBBB in ECG, 7 (15.2%) | • Transient paroxysmal atrial fibrillation on day 8 hospitalisation, lasted for 1 day and subsided spontaneously without treatment, 1 (0.82%) | • Lower LVEF at baseline vs day 30 (0.42 versus 0.33) | 83 |
|                    |        |                        | • Trace to mild mitral regurgitation, 17 (36.9%) | • Significant hypotension during the hospitalisation period, 51 (50.4%) | • Lower FPV at baseline vs day 30 (69.6 versus 83.8 cm/s) |            |
|                    |        |                        | • Trace to mild aortic regurgitation, 2 (4.3%) | • Cardiomegaly in first week of hospitalization, 66.6% | • Lower doppler-derived CO at baseline vs day 30 (4.69 versus 5.49 L/min) |            |
|                    |        |                        | • Significantly higher left ventricular IMP at baseline vs day 30 (0.42 versus 0.33) | • Cardiomegaly in second week of hospitalization, 75.8% | • Lower Em at baseline vs day 30 (17.3 versus 19.3 cm/s) |            |
|                    |        |                        | • Isovolumetric relaxation time | • Cardiomegaly in third week of hospitalization, 4 (3.3%) |                              |            |
|                    |        |                        | NA |                              | Patients requiring mechanical ventilation had: |            |
|                    |        |                        | | • Lower LVEF at baseline | • Higher IMP at baseline |            |
|                    | Yu et al. | Hong Kong, 2006 Prospective, single center (121) | • Palpitation, 5 (4%) | • Transient paroxysmal atrial fibrillation on day 8 hospitalisation, lasted for 1 day and subsided spontaneously without treatment, 1 (0.82%) | | 85 |
|                    |        |                        | • Elevated CK, 31 (26%) | • Significant hypotension during the hospitalisation period, 51 (50.4%) | |            |
|                    |        |                        | • No significant increase in troponin or CK-MB | • Cardiomegaly in first week of hospitalization, 66.6% | |            |
|                    |        |                        | • Tachycardia, 87 (71.9%) | • Cardiomegaly in second week of hospitalization, 75.8% | |            |
|                    |        |                        | • Significant sinus bradycardia, 18 (14.9%) | • Cardiomegaly in third week of hospitalization, 4 (3.3%) | |            |
|                    | Gu et al. | China, 2005 Retrospective, multi center (16) | • No obvious pathologic change in the heart. Lymphocytes and monocytes were found in some of these organs, mostly within vessels | • Transient paroxysmal atrial fibrillation on day 8 hospitalisation, lasted for 1 day and subsided spontaneously without treatment, 1 (0.82%) | |            |
|                    |        |                        | | • Significant hypotension during the hospitalisation period, 51 (50.4%) | • Cardiomegaly in first week of hospitalization, 66.6% |            |
|                    |        |                        | | • Cardiomegaly in second week of hospitalization, 75.8% | • Cardiomegaly in third week of hospitalization, 4 (3.3%) |            |
|                    |        |                        | | | |            |
|                    | Booth et al. | Canada, 2003 Retrospective, multicenter (144) | • Tachycardia | • Increased CK was significantly associated with poor outcome. | | 71 |
|                    |        |                        | • Abnormal CK, 43/109 (39%) | • Transient paroxysmal atrial fibrillation on day 8 hospitalisation, lasted for 1 day and subsided spontaneously without treatment, 1 (0.82%) | • Increased CK did not affect mortality. |            |
|                    | Chen et al. | China, 2003 Prospective, single centre (115) | | • Increased CK was significantly associated with poor outcome. | • Transient paroxysmal atrial fibrillation on day 8 hospitalisation, lasted for 1 day and subsided spontaneously without treatment, 1 (0.82%) | 85 |
|                    |        |                        | • Tachycardia | • Transient paroxysmal atrial fibrillation on day 8 hospitalisation, lasted for 1 day and subsided spontaneously without treatment, 1 (0.82%) | • Increased CK did not affect mortality. |            |
|                    | Choi et al. | Hong Kong, 2003 Retrospective cohort, single center. (267) | • CK was not elevated significantly in confirmed SARS cases. | • Transient paroxysmal atrial fibrillation on day 8 hospitalisation, lasted for 1 day and subsided spontaneously without treatment, 1 (0.82%) | • Post mortem analysis of 2 bodies revealed pulmonary thromboembolism as a cause for one of the deaths | 83 |
|                    |        |                        | | • Transient paroxysmal atrial fibrillation on day 8 hospitalisation, lasted for 1 day and subsided spontaneously without treatment, 1 (0.82%) | • Post mortem analysis of 2 bodies revealed pulmonary thromboembolism as a cause for one of the deaths |            |
|                    | Lee et al. | Hong Kong, 2003 Prospective, single center (138) | • Elevated CK levels, 44 (32.1%) | • Transient paroxysmal atrial fibrillation on day 8 hospitalisation, lasted for 1 day and subsided spontaneously without treatment, 1 (0.82%) | • Post mortem analysis of 2 bodies revealed pulmonary thromboembolism as a cause for one of the deaths | 76 |
|                    |        |                        | | • Transient paroxysmal atrial fibrillation on day 8 hospitalisation, lasted for 1 day and subsided spontaneously without treatment, 1 (0.82%) | • Post mortem analysis of 2 bodies revealed pulmonary thromboembolism as a cause for one of the deaths |            |
|                    | Lee et al. | Singapore, 2003 Retrospective, single center (199) | | | Early Cause of death: | 83 |
|                    |        |                        | • Ischemic stroke, 4 (2.01%) | • Cardiac failure with septicemia shock, 1 (0.50%) | • Cardiac failure with septicemia shock, 1 (0.50%) |            |
|                    |        |                        | • DVT, 11 (5.52%) | • Ventricular fibrillation and end stage renal failure, 1 (0.50%) | • Ventricular fibrillation and end stage renal failure, 1 (0.50%) |            |
|                    |        |                        | • Pulmonary embolism, 7 (3.51%) | • Late (>7 days) cause of death: | • Late (>7 days) cause of death: |            |
|                    |        |                        | | • AMI, 1 (0.50%) | • AMI, 1 (0.50%) |            |

Abbreviations: AMI, acute myocardial infarction; CK-MB, Creatine Kinase MB; CO, cardiac output; COVID-19, Coronavirus Disease 2019; DCM, dilated cardiomyopathy; DVT, deep vein thrombosis; ECG, electrocardiography; FPV, flow propagation velocity; HscTnI, high sensitivity troponin I; ICU, Intensive Care Unit; IMP, myocardial performance index; IVRT, isovolumetric relaxation time; NA, not available; No, number; NT-proBNP, N-terminal pro-bnatriuretic peptide; RBBB, right bundle branch block; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VF, ventricular fibrillation; VT, ventricular tachycardia
Table 2. Included case studies in the manuscript

| Coronavirus family | Author | Place, year | Case Design (No) | Presenting history, sign and symptoms | Para-clinical evaluation | Outcome |
|--------------------|--------|-------------|------------------|---------------------------------------|--------------------------|---------|
| COVID-19           | Fried et al. | USA, 2020    | Case series (4)  | Case 1: 64 year-old female with hypertension and hyperlipidemia. Persistent chest pressure for two days. No remarkable sign on physical examination. Case 2: 38 year-old male with type 2 diabetes mellitus. One week of cough, pleuritic chest pain and progressive shortness of breath. Tachyypnea on physical examination. Case 3: 64 year-old female with non-ischemic cardiomyopathy (recent normalization of LVEF), atrial fibrillation, hypertension and diabetes. Non-productive cough and shortness of breath for two days. Blood pressure 153/120 mmHg, heart rate 100 bpm, and oxygen saturation 99%. Case 4: A 51 year-old man with heart transplantation in 2007 and renal transplantation in 2010. Intermittent fever, dry cough, and shortness of breath for nine days. | | | |
|                   | Hu et al. | China, 2020  | Case report      | Case 1: A 37-year-old male. Chest pain and dyspnoea and diarrhoea for 3 days. Blood pressure 80/50 mmHg. | Chest x ray: Significant enlargement of the heart. Chest CT: Pulmonary infiltration, enlarged heart, and pleural effusion. ECG: ST-segment elevation acute inferior myocardial infarction. CT coronary angiography: No coronary stenosis. Laboratory: Troponin T was more than 10,000 ng/L. CK-MB 112.9 ng/L. Natriuretic peptide BNP was up to 21,025 ng/L. | Case 1: On IABP and dobutamine infusion, her cardiac index and lactate normalized and her end-organ function remained stable. The troponin-I peaked at 18.6 ng/mL and subsequently trended down to 0.4 ng/mL. The IABP was weaned after 7 days and the patient remained hemodynamically stable off IABP and inotropes. On repeat echocardiography on hospital day 10, LVEF improved to 50% and wall thickness was reduced. Case 2: He developed a supraventricular tachycardia and was successfully cardioverted. Developed acidosis and low O2 saturation, and VV ECMO. Vasopressor due to low blood pressure. VAV ECMO. Decannulated from ECMO after 7 days and is hemodynamically stable, although he remains on mechanical ventilation. Case 3: Respiratory status worsened rapidly, requiring intubation. She developed hypotension and was started on vasopressors. Dobutamine was started but was discontinued when she developed polymorphonuclear leukocytosis tachycardia requiring cardioversion. IABP was considered but deferred due to improvement in the arterial lactate and blood pressure. Troponin levels remained relatively stable throughout (peak 214 ng/mL). She remains intubated on day 9 of her hospitalization due to agitation with ventilator weaning attempts. Case 4: Following admission, the mycophenolate mofetil was discontinued. Through the first five days of the hospitalization, the patient was intermittently febrile and his inflammatory markers remained persistently elevated, though he remained clinically stable. He was discharged home after 7 days in the hospital. | |
|                   | Inciardi et al. | Italy, 2020  | Case report      | Case 1: A healthy 53-year-old woman. Severe fatigue for 2 previous days. She denied chest pain, dyspnoea, and further symptoms. She reported having fever and cough the week before. Blood pressure 90/50 mmHg, heart rate 100 beats per minute, oxygen saturation of 98% while breathing ambient air, and body temperature of 36.6 °C. | ECG: Low voltage in the limb leads, minimal diffuse ST-segment elevation, and an ST-segment depression with T-wave inversion in lead V1 and aVR. Chest x ray: Unremarkable. Laboratory: Elevated high-sensitivity troponin T level of 5.24 ng/mL and CK-MB level of 20.3 ng/mL, elevated NT-pro BNP levels (56477 pg/mL). ECG: RWMA with EF 40%. Circumferential pericardial effusion that was most notable around the right cardiac chambers (maximum, 11 mm) without signs of tamponade. Coronary angiography: No obstructive CAD. CMR: Confirmed the increased wall thickness with diffuse biventricular hypokinesia, especially in the apical segments and severe LV dysfunction (LVEF of 35%). T2 mapping sequences showed marked biventricular myocardial interstitial diffuse late gadolinium enhancement. The myocardial damage pattern of late gadolinium enhancement fulfilled all the Lake Louise criteria for the diagnosis of acute myocarditis. | Low BP. Dobutamine. TTE performed on day 6, revealed a significant reduction of LV wall thickness (interventricular septum, 11 mm and posterior wall, 10 mm), and improvement of LVEF to 44%, and a slight decrease of pericardial effusion (maximum, 8-9 mm). At the time of submission the patient was hospitized with progressive clinical and hemodynamic improvement. | |
Table 2. Continues

| Coronavirus family | Author | Place, year | Design (No) | Presenting history, sign and symptoms | Para-clinical evaluation | Outcome |
|--------------------|--------|-------------|-------------|---------------------------------------|-------------------------|---------|
| SARS               | Xu et al. | China, 2020 | Case report | A 50-year-old man. Symptoms of fever, chills, cough, fatigue and shortness of breath. | Chest x-ray: showed multiple patchy shadows in both lungs. | Sudden Cardiac arrest on day 14. Died. Biopsy of the heart showed a few interstitial mononuclear inflammatory infiltrates, but no other substantial damage in the heart tissue. |
|                   | Ding et al. | China, 2003 | Case series (3) | A 45-year-old woman. 4-day history of fluctuating fever up to 39°C, dry cough with shortness of breath, and diarrhea. | ECG: New T-wave inversion in the precordial leads. Laboratory: CK and cardiac troponin T levels were normal. TTE: normal left ventricular function with no regional wall motion abnormalities or pericardial effusion. Chest x-ray: right middle zone ground-glass haziness. Angiography: normal coronary arteries. High-resolution CT scan (HRCT): presence of a pneumomediastinum. | Despite maximized medical treatment, she still complained of recurrent chest pain with reversible ECG changes of T-wave inversion in the precordial leads over the subsequent 6 days. Her chest pain gradually subsided with analgesics and the ECG showed normalization of T-waves in the precordial leads during the subsequent convalescent period. |
|                   | Tak-Sun et al. | China, 2003 | Case report | Case 1: A 68-year-old woman, no risk factor with developed SARS that was complicated by respiratory failure, non-ST elevation acute myocardial infection (AMI). Case 2: A 64-year-old woman. Case 3: A 54-year-old female with dyslipidemia. Case 4: A 63-year-old man, with diabetes hypertension and IHD. 2 weeks after admission he developed partial hemispheric syndrome. Case 5: A 39-year-old man complicated with AMI, and cardiac arrhythmias. | Laboratory: elevated troponin-I level of 1.13 µg/L and an elevated pro-brain natriuretic peptide level of 6000 pg/ml, which increased to 8906 pg/ml on the second day. ECG: sinus tachycardia at a rate of 120 beats per minute and diffuse T-wave inversion. TTE: severe global LV systolic dysfunction and small pericardial effusion. CMR: LGE in favor of myocarditis. | Case 1: Aspirin was started and LMWH discontinued. She remains afebrile and hemiplegic. IVIG for 16 days. She was weaned off the ventilator two months later. Case 2: LMWH for 2 days. Ventilation. Died 1 week later. Case 3: Her blood pressure dropped to systolic 80mmHg, but responded promptly to desmopressin acetate (DDAVP), intravenous fluids and inotropic drugs. LMWH. IVIG. Died 2 days later. Case 4: No IVIG/No LMWH. Discharge. Case 5: No IVIG/No LMWH. Died. |
|                   | Umaphathi et al. | Singapore, 2003 | Case series (5) | Cases described in the study of Umaphathi et al. | | |
|                   | Chong et al. | Singapore, 2003 | Case series (14) | Cases described in the study of Umaphathi et al. | | 20.5% had deep vein thrombosis, 11.4%, showed clinical evidence of pulmonary embolism, 15.9% had myocardial infarction, and 4.5% had a cerebrovascular accident. |
|                   | Alloghani et al. | Saudi Arabia, 2016 | Case report | A previously healthy 60-year-old man. 4-day history of fever, shortness of breath, cough with yellowish sputum, and left side chest pain, which was worsened by inspiration. Physical examination showed a body temperature of 38°C, blood pressure of 115/70 mm Hg, pulse rate of 120 beats per minute, and respiratory rate of 24 per minute. The jugular venous pressure was elevated. | Laboratory: elevated troponin-I level of 1.13 µg/L and an elevated pro-brain natriuretic peptide level of 6000 pg/ml, which increased to 8906 pg/ml on the second day. ECG: sinus tachycardia at a rate of 120 beats per minute and diffuse T-wave inversion. TTE: severe global LV systolic dysfunction and small pericardial effusion. CMR: LGE in favor of myocarditis. | During the second week of admission, the patient required hemodialysis because of acute renal failure, which improved after 4 weeks. He also required intubation for mechanical ventilation because of respiratory failure that continued for 6 weeks. 1 month rehabilitation. LV systolic function remained severely impaired on echocardiography performed 3 months after the first one. He was discharged home when his clinical condition was stable. |
|                   | Al-Abdallat et al. | Jordan, 2014 | Case series (12)* | | | |

Abbreviations: AMI, acute myocardial infarction; CK-MB, Creatine Kinase MB; CMR, cardiac magnetic resonance imaging; COVID-19, Coronavirus Disease 2019; CT, computed tomography; ECG, electrocardiography; HscTnT, High sensitivity troponin T; IABP, intra-aortic balloon pump; IHD, ischemic heart disease; IVIG, Intravenous immunoglobulin; LGE, late gadolinium enhancement; LMWH, low molecular weight heparin; LV/EF, left ventricle ejection fraction; MCA, middle cerebral artery; MERS, middle east respiratory syndrome; No, number; NT-proBNP, N-terminal pro-brain natriuretic peptide; PCA, posterior cerebral artery; RWMA, regional wall motion abnormality; SARS, severe acute respiratory syndrome; TTE, transthoracic echocardiography; VAV, veno-arterial-venous; VV ECMO, veno-venous extracorporeal membrane oxygenation

* 124 interviews with 12 confirmed MERS infection
Coronaviruses and the cardiovascular system
J Cardiovasc Thorac Res, 2021, 13(2), 92-101

similarity between the three Coronavirus infections; however, available data are limited in MERS compared to SARS and COVID-19. All forms of thrombotic complications including acute coronary syndromes, marantic valvular vegetations, deep vein thrombosis, pulmonary emboli, thrombosis in pulmonary veins, multi organ thrombosis, and thrombotic cerebrovascular accidents have been reported in both SARS and COVID-19. It is suggested that the thrombotic complications may be due to excessive inflammation, cytokine storm, platelet activation, endothelial dysfunction, and stasis. Also, the limited data in MERS suggests that the hematologic and coagulation disorders as the cause of the thrombotic complications in fatal cases.17,29,39,42,46,49-51

Conclusion
In this study we tried to show the similarities and differences between the three types of Coronavirus. At the beginning the COVID-19 pandemic, the lessons from other Coronavirus epidemics suggested that the infection can be more severe and even fatal in those with cardiovascular co morbidities and a trigger for acute coronary syndromes, thrombotic complications and heart failure exacerbations; however, COVID-19 seems to be able to induce new cardiovascular pathologies and cardiovascular complications and appears to be a serious threat in addition to respiratory problems. It should also be clarified whether the nature of novel Coronavirus 2019 in terms of being more contagious and its spreading into different ethnicities and genetic backgrounds would be the cause of differences with its other ancestors. The long-term cardiovascular effects of COVID-19, along with the effect of future specific antiviral therapies are subject for further investigation. Further investigation is also needed to determine how patients with COVID-19 related cardiovascular complications should be followed in the long-term. Is there a possibility of recurrence in cases of myocarditis caused by the COVID-19? Will asymptomatic patients, with mild symptoms and people who have just suffered from respiratory problems without cardiovascular involvement, be at greater risk for heart diseases in the future?

Ethical approval
The study was approved at the institutional research ethics committee with IR.RHC.REC.1399.005 ethical code.

References
1. Coronavirus disease (COVID-19) situation reports. World Health Organization Web site. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed June 18, 2020.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/s0140-6736(20)30188-3
3. Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, et al. The variety of cardiovascular presentations of COVID-19. Circulation. 2020;141(23):1930-1936. doi:10.1161/circulationaha.120.047164
4. Ding Y, Wang H, Shen H, Li Z, Geng J, Han H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200(3):282-289. doi:10.1002/path.1440
5. Li SS, Cheng CW, Fu CL, Chan YH, Lee MP, Chan JW, et al. Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study. Circulation. 2003;108(15):1798-1803. doi:10.1161/01.cir.0000094737.21775.32
6. Teo TS, Tsui KL, Yam LY, So IK, Lau AC, Chan KK, et al. Occult pneumomediastinum in a SARS patient presenting as recurrent chest pain and acute ECG changes mimicking acute coronary syndrome. Respir Med. 2004;98(2):271-273. doi:10.1111/j.1460-244x.2003.01662.x
7. Umapathi T, Kor AC, Venketasubramanian N, Lim CC, Pang BC, Yeo TT, et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol. 2004;251(10):1227-1231. doi:10.1007/s00415-004-0519-8
8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b2535
9. Siririjy R, Lawton R, Gardner P, Armitage G. Reviewing studies with diverse designs: the development and evaluation of a new tool. J Eval Clin Pract. 2012;18(4):746-752. doi:10.1111/j.1365-2753.2013.01662.x
10. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811-818. doi:10.1001/jamacardio.2020.1017
11. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;92(7):797-806. doi:10.1002/jmv.25783
12. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10223):1054-1062. doi:10.1016/s0140-6736(20)30566-3
13. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. doi:10.1136/bmj.m1091
14. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care Med. 2020;211(1):1372-1379. doi:10.1164/rccm.202003-0543OC
15. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097-1100. doi:10.1093/cvr/cva078
16. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. doi:10.1056/NEJMoa200232
et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-1741. doi:10.1111/all.14238
18. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020;80(6):639-645. doi:10.1016/j.jinf.2020.03.019
19. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-810. doi:10.1001/jama cardiol.2020.0950
20. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi:10.1016/s0140-6736(20)30211-7
21. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481. doi:10.1016/s2213-2600(20)30079-5
22. Bonetti G, Manelli F, Patroni A, Bettinardi A, Borrelli G, Fiordalisi G, et al. Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy. Clin Chem Lab Med. 2020;58(7):1100-1105. doi:10.1515/cclm-2020-0459
23. Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of coronavirus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci. 2020;24(6):3404-3410. doi:10.26355/eurrev_202003_20711
24. Han H, Xie L, Liu R, Yang J, Liu F, Wu K, et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. J Med Virol. 2020;92(7):819-823. doi:10.1002/jmv.25809
25. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Analysis of 92 deceased patients with COVID-19. J Med Virol. 2020;92(11):2511-2515. doi:10.1002/jmv.25891
26. Deng Q, Hu B, Zhang Y, Wang H, Zhou X, Hu W, et al. Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China. Int J Cardiol. 2020;311:116-121. doi:10.1016/j.ijcard.2020.03.087
27. Hong KS, Lee KH, Chung HJ, Shin KC, Choi EY, Jin HJ, et al. Clinical features and outcomes of 98 patients hospitalized with SARS-CoV-2 infection in Daegu, South Korea: a brief descriptive study. Yonsei Med J. 2020;61(3):431-437. doi:10.3349/yjm.2020.61.3.431
28. Zheng Y, Xu H, Yang M, Zeng Y, Chen H, Liu R, et al. Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. J Clin Virol. 2020;127:104366. doi:10.1016/j.jcv.2020.104366
29. Yu CM, Wong RS, Wu EB, Kong SL, Wong J, Yip GW, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82(964):140-144. doi:10.1136/pgmj.2005.037513
30. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2000;192(3):415-424. doi:10.1084/jem.200050828
31. Booth CM, Matukas LM, Tomlinson GA, Rachiis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289(21):2801-2809. doi:10.1001/jama.289.21.10C30885
32. Chan JW, Ng CK, Chan YH, Mok TY, Lee S, Chu SY, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003;58(8):686-689. doi:10.1136/thorax.58.8.686
33. Choi KW, Chau TN, Tsang O, Tso E, Chiu MC, Tong WL, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med. 2003;139(9):715-723. doi:10.7326/0003-4819-139-9-20031104-00005
34. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1986-1994. doi:10.1056/NEJMoa030685
35. Lew TW, Kwek TK, Tai D, Earnest A, Loo S, Singh K, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA. 2003;290(3):374-380. doi:10.1001/jama.290.3.374
36. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. Eur Heart J. 2021;42(2):206. doi:10.1093/euheartj/ehaa190
37. Inciardi RM, Lupi L, Zaccione G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):819-824. doi:10.1001/jamacardio.2020.1096
38. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-422. doi:10.1016/s2213-2600(20)30076-x
39. Chong PY, Chui P, Ling AE, Franks TJ, Tai DY, Leo YS, et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med. 2004;128(2):195-204. doi:10.1043/1543-2165(2004)128<195:eaddts.2.0.co;2
40. Alhoughani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med. 2016;36(1):78-80. doi:10.1414/0256-4947.2016.78
41. Al-Abdallat MM, Payne DC, Alqasrawi S, Rha B, Tohme RA, Abedi GR, et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis. 2014;59(9):1225-1233. doi:10.1093/cid/ciu359
42. Giannis D, Zigos IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362. doi:10.1016/j.jcv.2020.104362
43. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843-1844. doi:10.1001/jama.2020.3786
44. Ansari Ramandi MM, Baay M, Naderi N. Does the novel coronavirus 2019 like heart more than the other family members of coronaviruses? J Cardiovasc Thorac Res. 2020;12(2):156-157. doi:10.34172/jctr.2020.27
45. Wang Y, Burnier M, Detrick B, Hooks JJ. Genetic predisposition to coronavirus-induced retinal disease. Invest Ophthalmol Vis Sci. 1996;37(1):250-254.
Coronaviruses and the cardiovascular system

47. Hua A, O’Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. 2020;41(22):2130. doi:10.1093/eurheartj/ehaa253

48. Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911-915. doi:10.1002/ejhf.1828

49. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950-2973. doi:10.1016/j.jacc.2020.04.031

50. Lacour T, Semaan C, Genet T, Ivanes F. Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients. Catheter Cardiovasc Interv. 2021;97(2):E241-E243. doi:10.1002/ccd.28948

51. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. doi:10.1016/j.thromres.2020.04.024